Have any questions? 706-721-6582 or cts@augusta.edu
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-(NAL03-301)CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NALBUPHINE EXTENDED RELEASE TABLETS FOR THE TREATMENT OF CHRONIC COUGH IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS
Clinical Trial
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-(NAL03-301)CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NALBUPHINE EXTENDED RELEASE TABLETS FOR THE TREATMENT OF CHRONIC COUGH IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants with Idiopathic Pulmonary Fibrosis.
Eligibility Criteria
- INCLUSION: 1. Participants ?40 years old at the time of informed consent. 2. Chronic cough for ?8 weeks prior to Screening. EXCLUSION: 1. Hospitalization for any respiratory illness (including acute exacerbation of IPF) within 8 weeks prior to Screening. 2. Pregnant or lactating females.
RESEARCH. INNOVATION. DISCOVERY.